Pipeline candidate
Dolcanatide for ulcerative colitis
An investigational GC-C agonist reflecting Synergy’s continued investment in GI innovation.
Development focus
Advancing a targeted approach
Dolcanatide leverages the same GC-C agonist principles as TRULANCE® with a focus on ulcerative colitis. The program emphasizes robust clinical design, transparent safety monitoring, and alignment with regulatory guidance.
- Designed for inflammatory bowel disease populations
- Guided by learnings from TRULANCE clinical development
- Supports Synergy’s GI-focused pipeline strategy
Investigational status: Dolcanatide is not approved. Information is intended for awareness of Synergy’s research focus. Refer to TRULANCE for currently approved therapy details and Important Safety Information below.